Table 4. MiR-31-3p and miR-31-5p validated on the complete set of cetuximab samples from training set and validation set 1 (N = 69) and their correlation with TTP (weeks).

MiRNA	Patients (N = 69)	Median TTP (weeks)	Log-Rank P	Adjusted HR	95% CI	P
MiR-31-3p
Low, ≤ 0.0155	46	44	<0.0001	5.099	2.520 to 10.317	<0.001
High, > 0.0155	23	14
MiR-31-5p
Low, ≤ 0.1378	42	45	<0.0001	4.803	2.497 to 9.242	<0.001
High, > 0.1378	27	14